Synthon Pharmaceuticals Appoints Paul Roos as Chief Financial Officer

Published: May 07, 2012

Nijmegen, the Netherlands, 7 May 2012 – Synthon today announced that it has appointed Paul Roos as chief financial officer (CFO). Paul will also serve as a member of Synthon’s executive board.

Paul comes to Synthon from Kempen & Co, a Dutch merchant bank, where he worked for ten years, most recently as Executive Director of Corporate Finance. In this high-profile position, he was accountable for building and maintaining relationships, originating new mandates and executing transactions with a focus on European Life Sciences & Healthcare as well as European Cleantech companies. In this capacity, he concluded over 35 transactions across a broad range of industries.

Paul simultaneously obtained a master of econometrics (cum laude) and a master of business economics (cum laude) of the University of Amsterdam and followed exchange programs at New York University and UPF Barcelona.

Synthon CEO Rudy Mareel commented: “I am excited to have Paul on-board as we enter a key phase in Synthon’s development. We are poised for significant expansion in our generics business with a strong and rejuvenated pipeline, while our biopharmaceuticals organization continues to mature with emerging partnerships and a sharper R&D focus. Paul’s deep knowledge of the healthcare and life sciences industry as well as his strong financial background are well-suited to our needs over the coming years and I am confident that he can add tremendous value to our company.”

About Synthon

Synthon, with headquarters in Nijmegen, the Netherlands is an international fast-growing pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune disease, multiple sclerosis and oncology. Our products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon employs about 1,400 staff at 11 sites worldwide, and in 2011 it recorded a turnover of EUR 260 million. For more information, go to

Back to news